Medicine name
International non-proprietary name (INN)
Therapeutic area
MA date
MA holder/ company name
Esperoct Turoctocog alfa pegol Hemophilia A 20/06/2019 Novo Nordisk A/S
Jivi Damoctocog alfa pegol Hemophilia A 22/11/2018 Bayer AG
Hemlibra Emicizumab Hemophilia A 23/02/2018 Roche Registration Limited
Adynovi Rurioctocog alfa pegol Hemophilia A 8/01/2018 Baxalta Innovations GmbH
Refixia Nonacog beta pegol Hemophilia B 2/06/2017 Novo Nordisk A/S
Vihuma Simoctocog alfa Hemophilia A 13/02/2017 Octapharma AB
Afstyla Lonoctocog alfa Hemophilia A 4/01/2017 CSL Behring GmbH
Alprolix Eftrenonacog alfa Hemophilia B 12/05/2016 Swedish Orphan Biovitrum AB (publ)
Idelvion Albutrepenonacog alfa Hemophilia B 11/05/2016 CSL Behring GmbH
Kovaltry Octocog alfa Hemophilia A 18/02/2016 Bayer Pharma AG
Elocta Efmoroctocog alfa Hemophilia A 18/11/2015 Swedish Orphan Biovitrum AB (publ)
Obizur Susoctocog alfa Hemophilia A 11/11/2015 Baxalta Innovations GmbH
Rixubis Nonacog gamma Hemophilia B 19/12/2014 Baxalta Innovations GmbH
Nuwiq Simoctocog alfa Hemophilia A 22/07/2014 Octapharma AB
NovoEight Turoctocog alfa Hemophilia A 13/11/2013 Novo Nordisk A/S
Voncento Human coagulation factor VIII/human von willebrand factor Hemophilia A, von Willebrand Diseases 12/08/2013 CSL Behring GmbH
Advate Octocog alfa Hemophilia A 2/03/2004 Takeda Manufacturing Austria AG
Kogenate Bayer Octocog alfa Hemophilia A 4/08/2000 Bayer AG
Helixate NexGen Octocog alfa Hemophilia A 4/08/2000 Bayer AG
ReFacto AF Moroctocog alfa Hemophilia A 13/04/1999 Pfizer Europe MA EEIG
BeneFIX Nonacog alfa Hemophilia B 27/08/1997 Pfizer Europe MA EEIG
NovoSeven Eptacog alfa (activated) Hemophilia B, Thrombasthenia, Factor VII Deficiency, Hemophilia A 23/02/1996 Novo Nordisk A/S